Editor | ScienceAI
Authors: This article is co-authored by leading researchers from Tsinghua University, the Gaoling School of Artificial Intelligence at Renmin University of China, and the AI Drug Discovery team at ByteDance. The first author, Xiangzhe Kong, hails from the Natural Language Processing and Social Humanities Computing Laboratory (TsinghuaNLP) at Tsinghua University, under the guidance of Professor Yang Liu. His research primarily focuses on geometric deep learning for structure-based drug molecule design.
Introduction: The Challenge of Targeted Drug Molecule Design
In the ever-evolving landscape of drug discovery, the design of targeted drug molecules remains a complex and multifaceted challenge. Different molecular types—antibodies, peptides, and small molecules—each bring unique advantages and complexities to the table, necessitating tailored design strategies. Small molecules, with their superior pharmacokinetic properties and cell permeability, are often the go-to for targeting intracellular proteins and developing oral medications. Peptides, bridging the gap between small molecules and biologics, offer extended binding interfaces capable of modulating protein-protein interactions that are typically too large and flat for small molecules to target effectively. Antibodies, with their exceptional specificity and affinity, dominate in therapeutic areas requiring precise recognition, such as cancer and autoimmune diseases.
Despite these advancements, current computational methods for drug molecule generation are siloed within specific molecular domains. For instance, small molecule generation models based on atomic autoregressive or diffusion models cannot easily extend to larger molecular structures like antibodies. Conversely, antibody generation frameworks, tailored for amino acid representation, lack the flexibility to expand to other molecular types. This compartmentalization limits the potential for cross-molecular insights and innovations.
The UniMoMo Breakthrough: A Unified Approach
At the International Conference on Machine Learning (ICML) 2025, the UniMoMo team introduced a groundbreaking solution to this fragmentation: a unified latent space diffusion model capable of generating targeted drug molecules across antibodies, peptides, and small molecules. This novel approach not only addresses the limitations of existing methods but also opens new avenues for integrated drug discovery and development.
Bridging the Gap with Latent Space Diffusion
The core innovation of UniMoMo lies in its latent space diffusion model, which enables the unified generation of diverse molecular types. By leveraging the power of geometric deep learning, the model captures the intricate structural nuances of different molecules, facilitating accurate and efficient design strategies.
What is Latent Space Diffusion?
Latent space diffusion is a generative modeling technique that involves learning a probability distribution over the latent space of a given data type—in this case, molecular structures. The model iteratively refines this distribution through a process akin to diffusion, gradually transforming a simple initial distribution into the complex target distribution of molecular structures.
Unifying Molecular Design
The UniMoMo model’s ability to unify antibody, peptide, and small molecule generation stems from its innovative architecture, which integrates geometric deep learning with latent diffusion. This integration allows the model to capture the geometric and structural intricacies of various molecular types, thereby enabling cross-domain insights and innovations.
Key Features of UniMoMo
-
Geometric Deep Learning: By employing geometric deep learning, UniMoMo effectively models the 3D structures of molecules, capturing essential spatial relationships and interactions that are critical for drug efficacy and specificity.
-
Cross-Molecular Flexibility: Unlike previous models constrained to single molecular domains, UniMoMo’s architecture is inherently flexible, accommodating the diverse structural characteristics of antibodies, peptides, and small molecules.
-
Enhanced Accuracy and Efficiency: Leveraging latent diffusion, UniMoMo achieves superior accuracy in predicting molecular structures, significantly reducing the time and resources required for drug discovery.
-
Integrated Drug Discovery: The unified approach of UniMoMo fosters collaboration and data sharing across different molecular domains, paving the way for holistic drug discovery pipelines.
The Impact on Drug Discovery and Development
The introduction of UniMoMo’s latent space diffusion model marks a significant milestone in computational drug discovery. By enabling the simultaneous generation and optimization of antibodies, peptides, and small molecules, UniMoMo offers numerous benefits to researchers and pharmaceutical companies alike.
Views: 0